The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Drozhdina M.B.

Kirov State Medical University

Koshkin S.V.

Kirov State Medical University

Iutinskaya A.O.

Kirov Region Clinical Dermatological and Venerological Hospital

Modern concept of the etiology, pathogenesis, clinical presentation, diagnosis, and treatment of Lever-type bullous pemphigoid (in Russian only)

Authors:

Drozhdina M.B., Koshkin S.V., Iutinskaya A.O.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2018;17(5): 53‑58

DOI: 10.17116/klinderma20181705153

Read: 6572 times

Download PDF (RU)
Contact the author
Table of contents

MODERN CONCEPT OF THE ETIOLOGY, PATHOGENESIS, CLINICAL PRESENTATION, DIAGNOSIS, AND TREATMENT OF LEVER-TYPE BULLOUS PEMPHIGOID (IN RUSSIAN ONLY)
MODERN CONCEPT OF THE ETIOLOGY, PATHOGENESIS, CLINICAL PRESENTATION, DIAGNOSIS, AND TREATMENT OF LEVER-TYPE BULLOUS PEMPHIGOID (IN RUSSIAN ONLY)

To cite this article:

Drozhdina MB, Koshkin SV, Iutinskaya AO. Modern concept of the etiology, pathogenesis, clinical presentation, diagnosis, and treatment of Lever-type bullous pemphigoid (in Russian only). Russian Journal of Clinical Dermatology and Venereology. 2018;17(5):53‑58. (In Russ.)
https://doi.org/10.17116/klinderma20181705153

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
IgM-dependent bullous pemphigoid. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):191-197
Effi­cacy of dupi­lumab application in bullous pemphigoid proceeding in presence of bronchial asthma. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):204-209
Clinical and immu­nological rela­tionships in patients with early schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42
The effect of the iron III poly­saccharide complex use on the cyto­kines, natriuretic peptide and erythropoietin levels in patients with chro­nic heart failure acco­mpanied with anemia. Russian Journal of Preventive Medi­cine. 2025;(3):80-86
Study of serum cyto­kine concentration in primary patients with gastric cancer. P.A. Herzen Journal of Onco­logy. 2025;(2):25-29
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
Asso­ciations of gene­tic poly­morphisms in key inflammatory response genes with the risk of chro­nic apical periodontitis deve­lopment. Russian Journal of Stomatology. 2025;(2):52-56
Proinflammatory cyto­kines — as a marker of the effe­ctiveness of neuroprotection in children with peri­natal nervous system damage. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):62-66
Myokines — the cardiometabolic risk pote­ntial biomarkers. Russian Journal of Preventive Medi­cine. 2025;(7):119-126
The role of neuroinflammation in the deve­lopment of seizure acti­vity and auto­nomic diso­rders in patients with epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):50-58
Abstract:

ABSTRACT We presented current data on the epidemiology of the Lever-type bullous pemphigoid and current incidence rate in various countries of the world. We describe the modern concept of predisposing factors, characteristic immunological changes, in particular, increase in the level of interleukin-16, the main chemotactic factor responsible for activation of CD4+ T-helpers in the skin, relationship with HLA histocompatibility antigens, the role of circulating autoantibodies, matrix metalloproteinases (MMP-2, MMP-9, and MMP-13), cytoplasmic and transmembrane proteins BP180 and BP230 in the pathogenesis of bullous pemphigoid. The role of autoantibodies to alpha-6 integrin and laminin-5, serum levels of monokines induced by σ-interferon (Th1-type chemokine), and serum levels of CCL17 and CCL22 (Tһ2-type chemokine) in clinical manifestations of the disease were also mentioned. Current ideas about the clinical presentation of the disease and staging of the process are described. Modern preparations for treatment of Lever-type bullous pemphigoid, including biologicals (rituximab, omalizumab) are described. We report a case of bullous pemphigoid in a patient with underlying chronic intake of non-steroidal anti-inflammatory drugs. The anticipated effect of etiotropic, pathogenetic, and symptomatic therapy complying with the standards of specialized medical care for bullous pemphigoid was observed.

Keywords:

bullous pemphigoid
immunogenetic predisposition according to the HLA system
circulating autoantibodies
cytokines
chemokines
BP180 and BP230 antigens

Authors:

Drozhdina M.B.

Kirov State Medical University

Koshkin S.V.

Kirov State Medical University

Iutinskaya A.O.

Kirov Region Clinical Dermatological and Venerological Hospital

Close metadata

References:

  1. Maria Isabel Martinez-De Pablo, Maria Antonia González-Enseñat, Asunción Vicente. Childhood bullous pemphigoid. Clinical and immunological findings in a series of 4 cases. Arch Dermatol. 2007;143(2):215-220. https://doi.org/10.1001/archderm.143.2.215
  2. Gajic-Veljic M, Nikolic M, Medenica L. Juvenile bullous pemphigoid: the presentation and follow-up of six cases. J Eur Acad Dermatol Venereol. 2010 Jan;24:69-72. https://doi.org/10.1111/j.1468-3083.2009.03264x
  3. Guidelines for the management of bullous pemphigoid. British Association of Dermatologists. 2012.
  4. Federalnye klinicheskie rekomendacii. Dermatovenerologiya 2015: Bolezni kozhi. Infekcii, peredavaemye polovym putem. 5-e izd. Pererab. i dop. M. 2016. (In Russ.).
  5. Chen R, Ning G, Zhao ML, et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest. 2001 Oct; 108(8):1151-1158. https://doi.org/10.1172/JCI11494
  6. Iwata H, Kamio N, Aoyama Y, et al. IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J Invest Dermatol. 2009 Apr;129(4):919-926. https://doi.org/10.1038/jid.2008.305
  7. Schmidt E, Obe K, Brocker EB, et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000 Feb; 136(2):174-178. https://doi.org/10.1001/archderm.136.2.174
  8. Zhou XP, Liu B, Xu Q, et al. Serum levels of immunoglobulins G1 and G4 targeting the non-collagenous 16A domain of BP180 reflect bullous pemphigoid activity and predict bad prognosis. J Dermatol. 2015 Aug 24. https://doi.org/10.1111/1346-8138.13051
  9. Kiss M, Perenyi A, Marczinovits I, et al. Autoantibodies to human alpha6 integrin in patients with bullous pemphigoid. Ann N Y Acad Sci. 2005 Jun;1051:104-110.
  10. Bekou V, Thoma-Uszynski S, Wendler O, et al. Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA. J Invest Dermatol. 2005 Apr;124(4):732-740. https://doi.org/10.1111/j.0022-202X.2005.23646.x
  11. Drozhdina MB, Koshkin SV. Modern concept of the clinical presentation, diagnosis, and treatment of bullous pemphigoid. Literature review. Vestnik dermatologii i venerologii. 2017;(6):47-53. (In Russ.).
  12. Frezzolini A, Cianchini G, Ruffelli M, et al. Interleukin-16 expression and release in bullous pemphigoid. Clin Exp Immunol. 2004 Sep;137(3):595-600. https://doi.org/10.1111/j.1365-2249.2004.02570x
  13. Echigo T, Hasegawa M, Shimada Y, et al. Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases. Arch Dermatol Res. 2006 Jun;298(1):38-45. https://doi.org/10.1007/s00403-006-0661-5
  14. Niimi Y, Pawankar R, Kawana S. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid. Int Arch Allergy Immunol. 2006;139(2):104-113. https://doi.org/10.1159/000090385
  15. Drozhdina MB, Koshkin SV. Modern view of the clinic, diagnosis and treatment of vulgar pemphigus. Presentation of cases. J Immunopathol allergol infectol. 2017;(4):6-12. (In Russ.). https://doi.org/10.14427/jipai/2017/3/68
  16. Stausbol-Gron B, Deleuran M, Sommer Hansen E, et al. Development of bullous pemphigoid during treatment of psoriasis with adalimumab. Clin Exp Dermatol. 2009 Oct;34:e285-e286. https://doi.org/10.1111/j.1365-2230.2008.03204x
  17. Marina Eskin-Schwartz, Drozhdina M, Ofer Sarig, et al. Epidermolytic Ichthyosis Sine Epidermolysis. Am J Dermatopathol. 2017;0:1-5. https://doi.org/10.1097/DAD.0000000000000674
  18. Wong SS, Rajakulendran S, Chow E. Bullous pemphigoid associated with carcinoma of the rectum. J. Hong Kong Geriatr. Soc.1996;7(1):14-17.
  19. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J. Clin. 2011;61(2):69-90. https://doi.org/10.3322/caac.20107
  20. Terra JB, Potze WJ, Jonkman MF. Whole body application of a potent topical corticosteroid for bullous pemphigoid. J Eur Acad Dermatol Venereol. 2013 Apr 3. https://doi.org/10.1111/jdv.12153
  21. Gual A, Iranzo P, Mascaró JrJM. Treatment of bullous pemphigoid with low-dose oral cyclophosphamide: a case series of 20 patients. J Eur Acad Dermatol Venereol. 2013 Apr 13. https://doi.org/10.1111/jdv.12155
  22. Iwata Y, Komura K, Kodera M, et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol. 2008 Jan;144(1):41-48. https://doi.org/10.1001/archdermatol.2007.9
  23. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol. 2004 Nov;51(5):817-819. https://doi.org/10.1016/j.jaad.2004.06.007
  24. Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006 Oct 26;355(17):1772-1779. https://doi.org/10.1056/NEJMoa062930
  25. Dupuy A, Viguier M, Bedane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 2004 Jan;140(1):91-96. https://doi.org/10.1001/archderm.140.1.91
  26. Reguiaï Z, Tchen T, Perceau G, et al. Efficacy of rituximab in a case of refractory bullous pemphigoid. Ann Dermatol Venereol. 2009 May;136(5):431-434.
  27. Balakirski G, Alkhateeb A, Merk HF, et al. Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature. J Eur Acad Dermatol Venereol. 2016 Jun 29. https://doi.org/10.1111/jdv.13758
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.